Standard BioTools Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Stockholders held on June 15, 2022. The company, Standard BioTools Inc., is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol "LAB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 18, 2022), the company had 77,252,135 shares of common stock, 127,780 shares of Series B-1 Convertible Preferred Stock, and 127,779 shares of Series B-2 Convertible Preferred Stock outstanding. Approximately 88.55% of total voting power was represented at the meeting. Key outcomes include:
- Election of Class III Directors: Laura M. Clague and Frank Whitney, Ph.D. were elected to serve until the 2025 annual meeting.
- Executive Compensation: The advisory vote to approve executive compensation for the year ended December 31, 2021, was approved with 116,251,305 votes for and 927,634 votes against.
- Accounting Firm Ratification: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2022 was ratified with 134,626,334 votes for and 116,591 votes against.
- Preferred Stock Elections: Series B-1 holders elected Eli Casdin, and Series B-2 holders elected Martin Madaus to the board of directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms and conversion rights of the Series B-1 and Series B-2 Convertible Preferred Stock.
- Confirm the tenure and responsibilities of the newly elected Class III directors (Clague and Whitney).
- Review the definitive proxy statement filed on April 29, 2022, for detailed compensation data referenced in the advisory vote.
- Monitor the company's financial performance in subsequent filings (10-Q/10-K) as this 8-K contains no financial data.